AYTU terminates Metadate CD license agreement with Lannett

AYTU BIOPHARMA, INC

Mutual termination effective June 23, 2026; certain provisions survive per Termination Agreement.
AYTU may continue to sell existing inventory and pay royalties until sales cease.
Metadate CD net revenue for quarter ended March 31, 2026 was $49,000, de minimis.
Termination Agreement will be filed as exhibit to FY 2026 10-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.